[1]黄永佳,杨 林,李 瑶,等.天冬酰胺酶-吴茱萸碱核壳型脂质纳米粒的药动学研究[J].中国药理学通报,2019,(09):1284-1289.[doi:10.3969/j.issn.1001-1978.2019.09.019]
 HUANG Yong-jia,YANG Lin,LI Yao,et al.Pharmacokinetic study on asparaginase-evodiamine loaded core-shell lipidic nanoparticles[J].Chinese Pharmacological Bulletin,2019,(09):1284-1289.[doi:10.3969/j.issn.1001-1978.2019.09.019]
点击复制

天冬酰胺酶-吴茱萸碱核壳型脂质纳米粒的药动学研究()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2019年09期
页码:
1284-1289
栏目:
论著
出版日期:
2019-09-09

文章信息/Info

Title:
Pharmacokinetic study on asparaginase-evodiamine loaded core-shell lipidic nanoparticles
文章编号:
1001-1978(2019)09-1284-06
作者:
黄永佳1杨 林2李 瑶3杨 强1杨仕钰1张景勍1
1.重庆医科大学药学院重庆高校药物工程研究中心,重庆 400016; 2.重庆医药高等专科学校药学系,重庆 401331; 3.重庆市公共卫生医疗救治中心药学部,重庆 400036
Author(s):
HUANG Yong-jia1 YANG Lin2 LI Yao3 YANG Qiang1 YANG Shi-yu1 ZHANG Jing-qing1
1.Chongqing Research Center for Pharmaceutical Engineering, College of Pharmacy,Chongqing Medical University,Chongqing 400016, China; 2.Chongqing Medical and Pharmaceutical College, Chongqing 401331,China; 3.Dept of Pharmacy, Chongqing Public Health Medical Center, Chongqing 400036, China
关键词:
天冬酰胺酶 吴茱萸碱 纳米粒 药代动力学 生物利用度 酶活性
Keywords:
asparaginase evodiamine nanoparticles pharmacokinetics bioavailability enzyme activity
分类号:
R-332; R284.1; R312; R345.69; R969.1; R977.3
DOI:
10.3969/j.issn.1001-1978.2019.09.019
文献标志码:
A
摘要:
目的 考察天冬酰胺酶-吴茱萸碱核壳型脂质纳米粒(asparaginase-evodiamine core-shell lipidic nanoparticles,AELNs)在大鼠体内的药动学行为,比较AELNs与游离天冬酰胺酶(asparaginase,ASNase)/吴茱萸碱(evodiamine,EVO)的生物利用度。方法 取18只SD大鼠,分别尾静脉注射AELNs、游离ASNase和游离EVO,给药后于不同时间点大鼠眼眶取血,分别采用Nessler试剂比色法和HPLC法测定血浆样品中ASNase和EVO的浓度,采用DAS(2.1.1版)软件计算药动学参数。结果 将游离ASNase制备成AELNs后,其药时曲线下面积和平均滞留时间分别提高了1.83倍和1.94倍。AELNs中EVO的药时曲线下面积约为游离EVO的28.94倍。结论 AELNs提高了ASNase和EVO在大鼠体内的生物利用度。
Abstract:
Aim To investigate the pharmacokinetic behavior of core-shell lipidic nanoparticles(AELNs) loaded with asparaginase and evodiamine in rats, and compare the bioavailability of AELNs with free asparaginase(ASNase)/evodiamine(EVO).Methods Eighteen male Sprague-Dawley rats were randomly divided into three groups and injected with AELNs, free ASNase and free EVO, respectively.After injection, blood samples were taken from the eyelids of rats at different time.The concentration of EVO and ASNase in plasma samples was determined by HPLC and Nessler reagent colorimetry method, respectively.To analyze the differences in pharmacokinetic behavior between AELNs and free ASNase or EVO, their pharmacokinetic parameters were calculated using DAS software.Results AUC(0~48 h) and MRT(0~48h) of ASNase in AELNs were 1.83 and 1.94 times higher than those of free ASNase, respectively.The AUC(0~48 h) of EVO in AELNs was 29.94 times that of free EVO.Conclusions Compared with free ASNase and EVO, AELNs have a higher bioavailability in rats.

参考文献/References:

[1] Mastour Tehrani S, Lu Y, Guerin G, et al.Temperature-invariant aqueous microgels as hosts for biomacromolecules[J].Biomacromolecules, 2015, 16(10):3134-44.
[2] Kumar K, Kaur J, Walia S, et al.L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia[J].Leuk Lymphoma, 2014, 55(2): 256-62.
[3] Siegel S E, Stock W, Johnson R H, et al.Pediatric-inspired treatment regimens for adolescents and young adults with philadelphia chromosome-negative acute lymphoblastic leukemia: a review[J].JAMA Oncol, 2018, 4(5): 725-34.
[4] Shiromizu S, Kusunose N, Matsunaga N, et al.Optimizing the dosing schedule of L-asparaginase improves its anti-tumor activity in breast tumor-bearing mice[J].J Pharmacol Sci, 2018, 136(4):228-33.
[5] Yu M, Henning R, Walker A, et al.L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer[J].J Cell Mol Med, 2012, 16(10):2369-78.
[6] Baskar G, Lalitha K, Aiswarya R, et al.Synthesis, characterization and synergistic activity of cerium-selenium nanobiocomposite of fungal l-asparaginase against lung cancer[J].Mater Sci Eng C Mater Biol Appl, 2018, 93:809-15.
[7] Hijiya N, van der Sluis I M.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia[J].Leuk Lymphoma, 2016, 57(4): 748-57.
[8] 李 瑶, 万胜利, 张永红, 等.载天冬酰胺酶磺丁基-β-环糊精脂质体的稳定性及相关机制[J].中国药理学通报, 2017, 33(11):1596-600.
[8] Li Y, Wan S L, Zhang Y H, et al.Stability and related mechanisms of sulfobutyl ether-β-cyclodextrin liposomes loaded with asparaginase[J].Chin Pharmacol Bull, 2017, 33(11): 1596-600.
[9] Du J, Sun Y, Lu Y Y, et al.Berberine and evodiamine act synergistically against human breast cancer MCF-7 cells by inducing cell cycle arrest and apoptosis[J].Anticancer Res, 2017, 37(11):6141-51.
[10] 石明芯, 胡江波, 晏声蕾, 等.微乳液递送吴茱萸碱的体外释放行为及在体吸收研究[J].中国药理学通报, 2018, 34(1):87-90.
[10] Shi M X, Hu J B, Yan S L, et al.In vitro release behavior and in vivo absorption of evodiamine by microemulsion delivery[J].Chin Pharmacol Bull, 2018, 34(1): 87-90.
[11] 张 雪, 刘宏明, 雷婷婷, 等.吴茱萸碱羟丙基-β-环糊精分子包合物的药代动力学[J].南方医科大学学报, 2016, 36(4):548-51.
[11] Zhang X, Liu H M, Lei T T, et al.Pharmacokinetics of evodiamine hydroxypropyl-β-cyclodextrin molecular inclusion complex[J].J Southern Med Univ, 2016, 36(4):548-51.
[12] 万胜利, 刘煜莹, 李 瑶, 等.壳聚糖修饰的L-天门冬酰胺酶脂质体血浆稳定性及药动学的初步研究[J].中国药学杂志, 2017, 33(11):1706-9.
[12] Wan S L, Liu Y Y, Li Y, et al.Preliminary study on plasma stability and pharmacokinetics of chitosan-modified L-asparaginase liposomes[J].Chin Pharm J, 2017, 33(11):1706-9.
[13] Sun X, Wang G, Zhang H, et al.The blood clearance kinetics and pathway of polymeric micelles in cancer drug delivery[J].ACS Nano, 2018, 12(6):6179-92.
[14] 马晓婷, 张石蕾, 由淑萍, 等.肉苁蓉苯乙醇总苷脂质体对大鼠T6肝星状细胞凋亡的影响及作用机制研究[J].中国药理学通报, 2018, 34(10):1450-5.
[14] Ma X T, Zhang S L, You S P, et al.Effects of cistanche glycosides on apoptosis of rat T6 hepatic stellate cells and its mechanism[J].Chin Pharmacol Bull, 2018, 34(10):1450-5.
[15] 吴 菲, 张龙骧, 李肖成, 等.载腺嘌呤甘草次酸修饰透明质酸纳米粒的制备及其对肝癌细胞增殖的影响[J].中国药理学通报, 2018, 34(5):706-12.
[15] Wu F, Zhang L X, Li X C, et al.Preparation and proliferation effect on hepatoma cells of adenine loaded glycyrrhetinic acid modified hyaluronic acid nanoparticles[J].Chin Pharmacol Bull, 2018, 34(5): 706-12.

相似文献/References:

[1]尹作静,曹志伟,闫鑫淼,等.黄连素和吴茱萸碱协同抗癌的miRNA网络机制研究[J].中国药理学通报,2017,(06):772.[doi:10.3969/j.issn.1001-1978.2017.06.008]
 YIN Zuo-jing,CAO Zhi-wei,YAN Xin-miao,et al.Study of synergistic mechanism in the combination of berberine and evodiamine from the perspective of miRNA[J].Chinese Pharmacological Bulletin,2017,(09):772.[doi:10.3969/j.issn.1001-1978.2017.06.008]

备注/Memo

备注/Memo:
收稿日期:2019-04-25,修回日期:2019-06-10
基金项目:重庆市基础与前沿研究计划重点项目(No cstc2015jcyjBX0027); 重庆市研究生科研创新项目(No CYS17172)
作者简介:黄永佳(1994-),女,硕士生,研究方向:药物新型给药系统与新技术,E-mail:1074717950@qq.com;
张景勍(1973-),女,博士,教授,博士生导师,研究方向:药物新型给药系统与新技术,通迅作者,E-mail:zjqrae01@163.com
更新日期/Last Update: 2019-08-14